Stereotactic radiotherapy for neovascular age-related macular degeneration: Year 2 results of the INTREPID study

Ophthalmology

Volumn 122, Issue 1, 2015, Pages 138-145

  Jackson, Timothy L ^a   Chakravarthy, Usha ^b   Slakter, Jason S ^c   Muldrew, Alyson ^b   Shusterman, E Mark ^d   O'Shaughnessy, Denis ^d   Arnoldussen, Mark ^d   Gertner, Michael E ^e   Danielson, Linda ^f   Moshfeghi, Darius M ^g  

^a KING S COLLEGE HOSPITAL   (United Kingdom)

^b QUEEN'S UNIVERSITY BELFAST   (United Kingdom)

^c Digital Angiography Reading Center   (United States)

^d Oraya Therapeutics Inc   (United States)

^e STANFORD UNIVERSITY   (United States)

^f INTERNATIONAL DRUG DEVELOPMENT INSTITUTE   (Belgium)

^g STANFORD UNIVERSITY SCHOOL OF MEDICINE   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

BEVACIZUMAB; RANIBIZUMAB; ANGIOGENESIS INHIBITOR; MONOCLONAL ANTIBODY; VASCULOTROPIN A; VEGFA PROTEIN, HUMAN;

AGE RELATED MACULAR DEGENERATION; ANGIOGRAPHY; ARTICLE; CENTRAL MACULAR THICKNESS; CONTROLLED STUDY; DOUBLE BLIND PROCEDURE; EXTERNAL BEAM RADIOTHERAPY; EYE PHOTOGRAPHY; FLUORESCENCE ANGIOGRAPHY; HUMAN; MAJOR CLINICAL STUDY; MICROANGIOPATHY; MICROVASCULARIZATION; MULTICENTER STUDY; OPTICAL COHERENCE TOMOGRAPHY; OPTICAL COHERENCE TOMOGRAPHY DEVICE; PRIORITY JOURNAL; RADIATION DOSE; RADIATION INJURY; RADIOTHERAPY; RANDOMIZED CONTROLLED TRIAL; SHAM PROCEDURE; STEREOTACTIC RADIOTHERAPY; STEREOTACTIC TREATMENT; SUBRETINAL NEOVASCULARIZATION; TREATMENT DURATION; TREATMENT RESPONSE; VISION; VISUAL ACUITY; X RAY SYSTEM; AGED; ANTAGONISTS AND INHIBITORS; CLINICAL TRIAL; FEMALE; INTRAVITREAL DRUG ADMINISTRATION; MALE; MIDDLE AGED; MULTIMODALITY CANCER THERAPY; PHYSIOLOGY; RADIOSURGERY; TREATMENT OUTCOME; VERY ELDERLY; WET MACULAR DEGENERATION;

AGED; AGED, 80 AND OVER; ANGIOGENESIS INHIBITORS; ANTIBODIES, MONOCLONAL, HUMANIZED; COMBINED MODALITY THERAPY; DOUBLE-BLIND METHOD; FEMALE; FLUORESCEIN ANGIOGRAPHY; HUMANS; INTRAVITREAL INJECTIONS; MALE; MIDDLE AGED; RADIOSURGERY; TOMOGRAPHY, OPTICAL COHERENCE; TREATMENT OUTCOME; VASCULAR ENDOTHELIAL GROWTH FACTOR A; VISUAL ACUITY; WET MACULAR DEGENERATION;

EID: 84920838933     PISSN: 01616420     EISSN: 15494713     Source Type: Journal    
DOI: 10.1016/j.ophtha.2014.07.043     Document Type: Article

References (22)

1. Owen CG, Jarrar Z, Wormald R, et al. The estimated prevalence and incidence of late stage age-related macular degeneration in the UK. Br J Ophthalmol 2012;96:752-6.
2. Munoz B, West SK, Rubin GS, et al. SEE Study Team. Causes of blindness and visual impairment in a population of older Americans: the Salisbury Eye Evaluation Study. Arch Ophthalmol 2000;118:819-25.
3. Finger RP, Fimmers R, Holz FG, Scholl HP. Prevalence and causes of registered blindness in the largest federal state of Germany. Br J Ophthalmol 2011;95:1061-7.
4. Bunce C, Xing W, Wormald R. Causes of blind and partial sight certifications in England and Wales: April 2007-March 2008. Eye (Lond) 2010;24:1692-9.
5. Heier JS, Brown DM, Chong V, et al; VIEW 1 and VIEW 2 Study Groups. Intravitreal aflibercept (VEGF Trap-Eye) in wet age-related macular degeneration. Ophthalmology 2012;119:2537-48.
6. Rosenfeld PJ, Brown DM, Heier JS, et al; MARINA Study Group. Ranibizumab for neovascular age-related macular degeneration. N Engl J Med 2006;355:1419-31.
7. Chakravarthy U, Houston RF, Archer DB. Treatment of age-related subfoveal neovascular membranes by teletherapy: a pilot study. Br J Ophthalmol 1993;77:265-73.
8. Petrarca R, Dugel PU, Nau J, et al. Macular epiretinal brachytherapy in treated age-related macular degeneration (MERITAGE): month 12 optical coherence tomography and fluorescein angiography. Ophthalmology 2013;120:328-33.
9. Jackson TL, Dugel PU, Bebchuk JD, et al; CABERNET Study Group. Epimacular brachytherapy for neovascular age-related macular degeneration (CABERNET): fluorescein angiography and optical coherence tomography. Ophthalmology 2013;120:1597-603.
10. Petrarca R, Dugel PU, Bennett M, et al. Macular epiretinal brachytherapy in treated age-related macular degeneration (MERITAGE): month 24 safety and efficacy results. Retina 2014;34:874-9.
11. Dugel PU, Petrarca R, Bennett M, et al. Macular epiretinal brachytherapy in treated age-related macular degeneration: MERITAGE Study: twelve-month safety and efficacy results. Ophthalmology 2012;119:1425-31.
12. Dugel PU, Bebchuk JD, Nau J, et al; CABERNET Study Group. Epimacular brachytherapy for neovascular age-related macular degeneration: a randomized, controlled trial (CABERNET). Ophthalmology 2013;120:317-27.
13. Jackson TL, Chakravarthy U, Kaiser PK, et al; INTREPID Study Group. Stereotactic radiotherapy for neovascular age-related macular degeneration: 52-week safety and efficacy results of the INTREPID Study. Ophthalmology 2013;120:1893-900.
14. Petrarca R, Jackson TL. Radiation therapy for neovascular age-related macular degeneration. Clin Ophthalmol 2011;5:57-63.
15. Jackson TL, Shusterman EM, Anoldussen, et al. Stereotactic radiotherapy for wet age-related macular degeneration (INTREPID): influence of baseline characteristics on clinical response. Retina August 6, 2014 [Epub ahead of print].
16. Kirwan JF, Constable PH, Murdoch IE, Khaw PT. Beta irradiation: new uses for an old treatment: a review. Eye (Lond) 2003;17:207-15.
17. Jackson TL, Danis RP, Goldbaum M, et al. Retinal vascular abnormalities in neovascular age-related macular degeneration. Retina 2014;34:568-75.
18. Petrarca R, Richardson M, Douiri A, et al. Safety testing of epimacular brachytherapy with microperimetry and indocyanine green angiography: 12-month results. Retina 2013;33:1232-40.
19. Christoforidis JB, Xie Z, Jiang A, et al. Serum levels of intravitreal bevacizumab after vitrectomy, lensectomy and non-surgical controls. Curr Eye Res 2013;38:761-6.
20. Kakinoki M, Sawada O, Sawada T, et al. Effect of vitrectomy on aqueous VEGF concentration and pharmacokinetics of bevacizumab in macaque monkeys. Invest Ophthalmol Vis Sci 2012;53:5877-80.
21. CATT Research Group. Ranibizumab and bevacizumab for neovascular age-related macular degeneration. N Engl J Med 2011;364:1897-908.
22. Comparison of Age-related Macular Degeneration Treatments Trials (CATT) Research Group, Martin DF, Maguire MG, Fine SL, et al. Ranibizumab and bevacizumab for treatment of neovascular age-related macular degeneration: two-year results. Ophthalmology 2012;119:1388-98.